Mid-cap buyers, improved capital raising climate, and reshoring of manufacturing are shaping how much and where biopharmas ...

In a quest to provide more relevant translational data, traditional in vivo models join forces with new approach methodologies.

There is little doubt that the biopharma sector is undergoing unprecedented levels of change right now. Its global supply chain is in a state of great change due to geopolitical and economic drivers, ...

Parabilis Medicines aims to raise up to $475 million in US IPO Biopharmaceutical company Parabilis Medicines said on Thursday it is aiming to raise as much ‌as $475 million in its U.S. initial public ...

Welcome to Fierce Biotech’s fifth annual layoff tracker, a resource designed to keep pace with the sector’s steady stream of workforce reductions. In 2025, industry layoffs continued to rise year over ...